AAV5-mediated targeted decorin gene therapy : effective and safe for corneal fibrosis [abstract]
Metadata[+] Show full item record
Corneal fibrosis is 3rd leading cause of global blindness according to WHO report. At present, no agents are proven to clinically reduce corneal fibrosis without causing significant side effects. It was hypothesized that decorin gene delivered into keratocytes prevents corneal fibrosis in the cornea in vivo by blocking transforming growth factor β (TGFb), which converts keratocyte to myofibroblasts and cause fibrosis.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.